EUVIMEDEUVIMED entdecken
Multizentrische Studie

Multicenter Retrospective Case Series on the Real‐World Experience With Sonidegib for the Management of Gorlin Syndrome

Gemma Pérez-Pastor, Dario Perosanz Lobo, Cristina Ciudad Blanco, Ricardo Fernández de Misa Cabrera, Francisco Vilchez-Marquez, Montserrat Bonfill Ortí, Víctor Gonzalez-Delgado iD, Mireia Yébenes Marsal, Elia Samaniego González, Laura García-Fernández iD, Alvaro Martínez-Domenech iD

Australasian Journal of Dermatology · 2025

DOI: 10.1111/ajd.14614 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Australasian Journal of Dermatology, 2025. Verfasst von Gemma Pérez-Pastor und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Consorcio Hospital General Universitario de Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Basal Cell Nevus Syndrome, Pyridines, Biphenyl Compounds, Antineoplastic Agents. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Sun Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gorlin syndrome (GS) is a hereditary genodermatosis characterised by the development of multiple basal cell carcinomas (BCC). The hedgehog pathway inhibitors (HPI) like sonidegib have been shown to be effective, but the frequency of adverse events (AE) limits their long‐term use. Dose modifications and off‐therapy periods are frequently necessary to improve tolerability.

Objectives

To describe the dosing regimens employed during treatment with sonidegib for GS in clinical practice and evaluate the efficacy and tolerability of its long‐term use.

Methods

Multicenter retrospective study involving 10 referral centres in Spain including patients with GS who received treatment with sonidegib for at least 12 weeks.

Results

Twenty‐four patients were included: 11 (45.8%) women and 13 (54.2%) men, with a mean age of 50.7 ± 12.1 years. The mean duration of treatment with sonidegib was 10.4 ± 5.1 months. Sonidegib was started at 200 mg daily in 22 (91.7%) patients. Thirteen (59.1%) of them switched to alternate‐day dosing motivated most frequently by the development of AEs (76.9%), and less frequently by dosing convenience (23.1%). Two patients followed on–off regimens. Four patients received an off‐label regimen of 2–3 tablets per week. Nine (37.5%) of the 24 patients achieved a complete response, 13 (54.2%) a partial response and 2 (8.3%) presented stable disease. Twenty (83.3%) patients presented at least one AE, the most frequent being alopecia (45.8%), followed by muscle cramps (37.5%), dysgeusia (29.2%), asthenia (29.2%), weight‐loss (20.8%), diarrhoea (12.5%) and nausea (8.3%).

Conclusions

Our data on the use of sonidegib for GS in clinical practice show similar response rates to those reported in previous studies and improved tolerability compared to pivotal studies. Regimen modifications are frequently used in clinical practice to improve AEs. Although the alternate‐day dose is the most common modification, dermatologists also resort to off‐label regimens for this purpose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basal Cell Nevus SyndromePyridinesBiphenyl CompoundsAntineoplastic AgentsHumansMaleFemaleRetrospective StudiesMiddle AgedAdultAgedAlopeciaSkin Neoplasms

Stichwörter der Autor:innen

Gorlin syndromebasal cell carcinomahedgehog inhibitornevoid basal cell carcinoma syndromesonidegibtherapy

Substanzen

sonidegibPyridinesBiphenyl CompoundsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Consorcio Hospital General Universitario de Valencia, Valencia, Spain.
  • Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, España.
  • Department of Dermatology, Hospital Gregorio Marañón, Madrid, Spain.
  • Department of Dermatology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
  • Department of Dermatology, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Department of Dermatology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

ORCID-Profile: Víctor Gonzalez-Delgado, Laura García-Fernández, Alvaro Martínez-Domenech

Förderung

  • Sun Pharma

Zitieren

APA

Pérez-Pastor, G., Perosanz Lobo, D., Ciudad Blanco, C., Fernández de Misa Cabrera, R., Vilchez-Marquez, F., Bonfill Ortí, M., Gonzalez-Delgado, V., Yébenes Marsal, M., Samaniego González, E., García-Fernández, L., & Martínez-Domenech, A. (2025). Multicenter Retrospective Case Series on the Real‐World Experience With Sonidegib for the Management of Gorlin Syndrome. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14614

Vancouver

Pérez-Pastor G, Perosanz Lobo D, Ciudad Blanco C, Fernández de Misa Cabrera R, Vilchez-Marquez F, Bonfill Ortí M, et al. Multicenter Retrospective Case Series on the Real‐World Experience With Sonidegib for the Management of Gorlin Syndrome. Australasian Journal of Dermatology. 2025. doi:10.1111/ajd.14614

BibTeX
@article{PrezPastor2025,
  author = {Pérez-Pastor, Gemma and Perosanz Lobo, Dario and Ciudad Blanco, Cristina and Fernández de Misa Cabrera, Ricardo and Vilchez-Marquez, Francisco and Bonfill Ortí, Montserrat and Gonzalez-Delgado, Víctor and Yébenes Marsal, Mireia and Samaniego González, Elia and García-Fernández, Laura and Martínez-Domenech, Alvaro},
  title = {Multicenter Retrospective Case Series on the Real‐World Experience With Sonidegib for the Management of Gorlin Syndrome},
  journal = {Australasian Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ajd.14614}
}
Kostenlos starten →